Celsion

company

About

Celsion is a biopharmaceutical company which develops innovative, targeted therapies that address unmet medical needs in oncology.

  • 11 - 50

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$20M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1982
Number Of Employee
11 - 50
Operating Status
Active

Celsion is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative cancer treatments, including immunotherapies and DNA-based therapies; and a platform for the development of nucleic acid vaccines currently focused on SARS-CoV2. The company’s product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, is under investigator-sponsored development for several cancer indications. Celsion also has two feasibility stage platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Celsion has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Nov 26, 2013 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 26, 2013 Post-IPO Debt $20M 1 Hercules Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Celsion is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Post-IPO Debt